(Reuters) – Supernus Pharmaceuticals Inc said on Tuesday its experimental drug for attention deficit hyperactivity disorder (ADHD) met the main goal of a late-stage study test in adults.
The drug, SPN-812, is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD in children 6 to 17 years of age.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Chris Reese)
